Cardiac amyloidosis presents a picture of hypertrophic cardiomyopathy with heart failure with preserved ejection fraction. It is largely underdiagnosed, especially in black Africans, and therefore falls under the category of heart disease classified as idiopathic. Light chain amyloidosis (AL) is mainly found in Caucasian subjects and the mutant variant of transthyretin (TTRm) in negroid subjects. Numerous studies have shown that ATTRm was found predominantly in black American and black British patients. In African countries the entity of idiopathic heart failure is quite important because of lack of diagnosis, ETT, MRI and immuno-histochemistry are expensive or not available. We can probably assume that the proportion of cardiac amyloidosis is quite important in black Africans. The question is if 99mTc-DPD really easy to perform, can probably help to investigate in the nuclear medicine department in Africa. No large-scale study has been able to demonstrate the prevalence or not of cardiac amyloidosis in black-African subjects and by extension reduce this nosological entity of idiopathic heart disease. The 99mTc-DPD scintigraphy using Perrugini’s visual sore allows localization and classification of amyloid damage. The mechanism of binding of 99mTc-DPD to amyloid fibril deposits is not well known, its binding to TTR-type (mutated or wild type) amyloidosis is greater than the AL variant. In the diagnostic algorithm, endomyocardial biopsy is the gold standard but remains invasive, ETT with the strain allows a presumptive diagnosis and remains an operative examination dependent and is not reproducible. Cardiac MRI allows some localization of amyloid deposits but still remains less sensitive than scintigraphy. In addition, performing the whole-body MRI is very restrictive (time, antenna change and cost). The aim of this literature review was to show the superiority of 99mTc-DPD scintigraphy compared to other diagnostic modalities and to consider its use given its simplicity when it comes to usage in Sub-Saharan Africa to diagnose the disease. cardiac amyloidosis and by extension reduce the number of cases of heart disease classified as idiopathic and thus allow early and appropriate management.
References
[1]
Merlini, G. and Bellotti, V. (2003) Molecular Mechanisms of Amyloidosis. The New England Journal of Medicine, 349, 583-596. https://doi.org/10.1056/NEJMra023144
[2]
Diallo, S., Diouf, B., Ka, F., et al. (2008) Amylose AL chez le noir africain: A propos de 4 cas senegalais. Medecine d’Afrique Noire, 55, 471.
[3]
James, P.D. and Owor, R. (1975) Systemic Amyloidosis in Ouganda: An Autopsy Study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 69, 480-483. https://doi.org/10.1016/0035-9203(75)90103-0
[4]
Mody, G., Bowen, R. and Meyers, O.L. (1984) Amyloidosis at Groote Schuur Hospital, Cape Town. South African Medical Journal, 66, 47-49.
[5]
MacIver, A.G. and Thomas, S.M. (1982) Protein AA Amyloidosis in Nigeria. The Journal of Tropical Medicine and Hygiene, 85, 209-212.
[6]
Diallo, S., Diouf, B., Niang, A., et al. (2005) Amylose renales AA compliquant une lepre lepromateuse: Revue de la litterature a propos d’un cas senegalais. Medecine Tropicale, 65, 605-607.
[7]
Lane, T., Fontana, M., Martinez-Naharro, A., et al. (2019) Outcome in Cardiac ATTR Amyloidosis. Circulation, 140, 16-26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169
[8]
Dungu, J.N., Papadopoulou, S.A., Wykes, K., Mahmood, I., Marshall, J., Valencia, O., Fontana, M., Whelan, C.J., Gillmore, J.D., Hawkins, P.N. and Anderson, L.J. (2016) Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. Circulation: Heart Failure, 9, e003352. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003352
[9]
Vrana, J.A., et al. (2009) Classification of Amyloidosis by Laser Microdissection and Mass Spectrometry-Based Proteomic Analysis in Clinical Biopsy Specimens. Blood, 114, 4957-4959. https://doi.org/10.1182/blood-2009-07-230722
[10]
Ando, Y., Nakamura, M. and Araki, S. (2005) Transthyretin-Related Familial Amyloidotic Polyneuropathy. Archives of Neurology, 62, 1057. https://doi.org/10.1001/archneur.62.7.1057
[11]
Jacobson, D.R., et al. (1996) Revised Transthyretin Ile 122 Allele Frequency in African-Americans. Human Genetics, 98, 236-238. https://doi.org/10.1007/s004390050199
[12]
Cristina, Q.C., Buxbaum, J.N. and Shah, A.M. (2015) The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. The New England Journal of Medicine, 372, 21-29. https://doi.org/10.1056/NEJMoa1404852
[13]
Shah, K.B., Mankad, A.K. and Castano, A. (2016) Transthyretin Cardiac Amyloidosis in Black Americans. Circulation: Heart Failure, 9, e002558. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002558
[14]
Perugini, et al. (2005) Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology, 46, 1076-1084. https://doi.org/10.1016/j.jacc.2005.05.073
[15]
Rapezzi, C., et al. (2009) Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types. Circulation, 120, 1203-1212. https://doi.org/10.1161/CIRCULATIONAHA.108.843334
[16]
Connors, L.H., et al. (2009) Cardiac Amyloidosis in African Americans: Comparison of Clinical and Laboratory Features of Transthyretin V122I Amyloidosis and Immunoglobulin Light Chain Amyloidosis. American Heart Journal, 158, 607-614. https://doi.org/10.1016/j.ahj.2009.08.006
[17]
Di Bella, G., Minutoli, F., Piaggi, P., Casale, M., Mazzeo, A., Zito, C., Oreto, G., Baldari, S., Vita, G., Pingitore, A., Khandheria, B.K. and Carerj, S. (2016) Quantitative Comparison between Amyloid Deposition Detected by (99m)Tc-Diphosphonate Imaging and Myocardial Deformation Evaluated by Strain Echocardiography in Transthyretin-Related Cardiac Amyloidosis. Circulation Journal, 80, 1998-2003. https://doi.org/10.1253/circj.CJ-16-0209
[18]
Perugini, E., et al. (2005) Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology, 46, 1076-1084. https://doi.org/10.1016/j.jacc.2005.05.073
[19]
Bokhari, S., Castano, A., Pozniakoff, T., Deslisle, S., Latif, F. and Maurer, M.S. (2013) 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis from the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging, 6, 195-201. https://doi.org/10.1161/CIRCIMAGING.112.000132
[20]
Minutoli, F., Di Bella, G., Mazzeo, A., Donato, R., Russo, M., Scribano, E. and Baldari, S. (2013) Comparison between (99m)Tc-diphosphonate Imaging and MRI with Late Gadolinium Enhancement in Evaluating Cardiac Involvement in Patients with Transthyretin Familial Amyloid Polyneuropathy. American Journal of Roentgenology, 200, W256-W265. https://doi.org/10.2214/AJR.12.8737
[21]
Bodez, D., et al. (2016) Les amyloses cardiaques: Les reconnaiître et les prendre en charge. La Presse Medicale, 45, 845-855. https://doi.org/10.1016/j.lpm.2016.07.001
[22]
Gallini, C., Tutino, F., Martone, R., et al. (2021) Semi-Quantitative Indices of Cardiac Uptake in Patients with Suspected Cardiac Amyloidosis Undergoing 99mTc-HMDP Scintigraphy. Journal of Nuclear Cardiology, 28, 90-99. https://doi.org/10.1007/s12350-019-01643-w
[23]
Singh, V., Falk, R., Di Carli, M.F., Kijewski, M., Rapezzi, C. and Dorbala, S. (2019) State-of-the-Art Radionuclide Imaging in Cardiac Transthyretin Amyloidosis. Journal of Nuclear Cardiology, 26, 158-173. https://doi.org/10.1007/s12350-018-01552-4
